|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Non-Insulin Antidiabetics – Incretin Mimetics – Leaders in a Diverse Pipeline
Datamonitor, May 2008, Pages: 294
The report expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.
Scope
- Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes.
- A detailed clinical and commercial assessment of all key emerging therapies.
- Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.
Highlights of this title
Incretin mimetics, GLP-1 agonists and DPP-IV inhibitors, are likely to be the most successful candidates in the pipeline. Pipeline incretin candidates are forecast to generate sales of $7,905m in the seven major markets in 2017
A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 137 candidates from 60 different mechanisms of action are in development
Big Pharma dominate the non-insulin antidiabetic pipeline as the disease is one of the few growth areas in the cardiovascular and metabolic disease areas. Sixteen of the top twenty drug companies have a non-insulin antidiabetic pipeline and between them are developing 52% of the pipeline
Key reasons to purchase this title
- Quantify the future drugs in the non-insulin antidiabetic market.
- Identify licensing opportunities based on company portfolio and market needs.
- Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.
Customers who bought this item also bought
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Stakeholder Insight: Diabetes
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Therapeutic Clinical Intelligence - Type-2 Diabetes Pipeline
Competitor Analysis: Diabetes Drug Pipeline
Diabetes Market Forecast to 2013
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth
Commercial Insight: Antidiabetics - DPP-IV Inhibitors Poised to Sweep the Market
Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015
Competitor Analysis: Insulin
|
|
|
|
